drugset / Trial / NCT02327793

Perfusion and Antihypertensive Therapy in Acute Ischemic Stroke

NCT02327793

Phase 2 Completed 65 enrolled University of Alberta
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to provide a description of blood flow changes in the brain after blood pressure lowering drugs are given. This information will be used by physicians to guide blood pressure lowering therapy in stroke patients in the future.

Timeline

Start
2009-06
Primary completion
2015-07
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Labetalol Small molecule 10 mg Intravenous
Subject Labetalol Small molecule 20 mg Intravenous
Subject Nitroglycerin Unknown 0.2 mg Other
Subject Nitroglycerin Unknown 0.3 mg Other

Indications